- The Dog Days of Drug Approvals, Drugwonks, Peter J. Pitts, August 21, 2015
Personalized Medicine
RECENT NEWS
New JCI Viewpoint: FDA Must Rethink How It Evaluates Precision Medicines for Rare Diseases
Authors argue that rare disease innovation requires learning more from fewer patients—not enrolling more patients... Read more
Qualifying Single-Source Drug Policy, Medicare Price Negotiation, and the Incentives for Meaningful Post-Approval Innovation
CMS should demand evidence from manufacturers and be prepared to defend its own assumptions about innovation. Its next st... Read more
Troubling Trends: Systemic Practices in Texas' Non-Profit Hospitals That Inflate Health Care Costs
Texas has an opportunity to lead rather than react. Better measurement would strengthen public confidence without diminis... Read more